Multinational biopharmaceutical company OPKO Health's (OPK) stock climbed nearly 13% in price last year when the company announced its plans to acquire ModeX Therapeutics. However, given the company's...
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
The company topped Q1 revenue estimates and announced a key new acquisition.
OPK earnings call for the period ending March 31, 2022.
OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 6.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKODr. Gary...
Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 5.61% and 3.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Investors in OPKO Health Inc saw new options begin trading today, for the May 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OPK options chain for the new...
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and regulatory approvals.